Several clinical trials with CAR T cells specific for different tumor antigens such as HER2 (NCT03696030), EpCAM (NCT02915445), MUC1 (NCT04020575 and NCT02587689) and mesothelin (NCT02792114), alone or in combination regimens, are currently ongoing in BC patients. Here, EPCAM is linked to breast cancer.